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Abstract
P. jiroveci (Pj) causes a potentially fatal pneumonia in immunocompromised patients and
the factors associated with a bad outcome are poorly understood. A retrospective analysis
on Pj pneumonia (PjP) cases occurring in Tor Vergata University Hospital, Italy, during the
period 2011–2015. The patients’ demographic, clinical and radiological characteristics and
the Pj genotypes were considered. The study population included 116 patients, 37.9% of
whom had haematological malignancy or underwent haematological stem cell transplanta-
tion (HSCT), 22.4% had HIV infection, 16.4% had chronic lung diseases (CLD), 7.8% had a
solid cancer, and 3.4% underwent a solid organ transplant (SOT). The remaining 12.1% had
a miscellaneous other condition. At univariate analysis, being older than 60 years was signif-
icantly correlated with a severe PjP (OR [95%CI] 2.52 [0.10–5.76]; p = 0.031) and death
(OR [95%CI] 2.44 [1.05–5.70]; p = 0.036), while a previous trimethoprim/sulfamethoxazole
(TMP/SMX) prophylaxis were significantly associated with a less severe pneumonia (OR
[95%CI] 0.35 [0.15–0.84], p = 0.023); moreover, death due to PjP was significantly more fre-
quent in patients with CLD (OR[95%CI] 3.26 [1.17–9.05]; p = 0.019) while, admission to the
Infectious Diseases Unit was significantly associated with fewer deaths (OR[95%CI] 0.10
[0.03–0.36], p = 0.002). At multivariate analysis, a better PjP outcome was observed in
patients taking TMP/SMX prophylaxis and that were admitted to the Infectious Diseases
Unit (OR[95%CI] 0.27 [0.07–1.03], p = 0.055, OR[95%CI] 0.16 [0.05–0.55]; p = 0.004,
respectively).
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In conclusion, in our study population, TMP/SMX prophylaxis and infectious disease spe-
cialist approach were variables correlated with a better PjP outcome.
Introduction
Pneumocystis jiroveci pneumonia (PjP) is a serious and potentially life-threatening fungal
infection that is mostly diagnosed in immune-compromised individuals. Before the 1980s, it
was recognized as a rare, but often fatal, infection that mainly affected patients with haemato-
logical malignancies. However, the worldwide epidemic of human immunodeficiency virus
(HIV) has dramatically increased the prevalence of PjP, and it has become the most common
and alarming complication of the late stages of HIV infection.
Over the last several decades, the introduction of antiretroviral therapy (ARV) dramatically
reduced the PjP incidence in HIV-positive patients; however, a new increase in the rate of this
pneumonia was reported in large epidemiological studies from France and England [1, 2].
These studies documented a major incidence of PjP in non-HIV-infected patients reaching
the levels observed in HIV-positive subjects. The growing number of longer-surviving patients
with protracted immunosuppression other than the patients who are traditionally considered
in the risk categories is the major cause attributed to this phenomenon. Solid organ transplant
(SOT), haematological stem cell transplants (HSCT), chronic lung diseases (CLD) and pro-
longed treatment with biological drugs (i.e., anti-TNF) or corticosteroids are considered con-
ditions that are associated with an increased risk for PjP development [3]. More efficient
laboratory tools for P. jiroveci (Pj) diagnosis and the consequent better ascertainment of PjP
cases were also considered the basis for the recent increase in PjP incidence.
Staining methods (May-Gru¨nwald-Giemsa, Gomori methenamine silver, Grocott) were
traditionally used to demonstrate Pj in biological specimens, however, despite their good spec-
ificity, they failed in detection of low levels of Pj in sputum samples [4, 5]. About twenty years
ago, these stains were supplanted by direct or indirect immunofluorescence (IF) using anti—
Pj monoclonal antibodies: among microscopic methods, IF is considered the most sensitive
assay for Pj detection [4]. In recent years, several polymerase chain reaction (PCR) assays
directed at various gene targets have been developed to detect Pj DNA in respiratory secretions
[6–8]. PCR and real time PCR assays are now recommended, in combination of IF, to improve
sensitivity and differentiate between PjP and Pj colonization [3, 9]. Moreover, many genetic
typing methods and the study of a large number of Pj gene loci demonstrated a high level of
genetic variability of Pj [10–12].
Although these new techniques greatly improve the diagnosis and possibility of early ther-
apy, PjP remains a severe and potentially life-threatening infection. A worse outcome and a
higher mortality rate of PjP was reported in HIV-negative patients with respect to patients
with HIV-infections [13,14]. Numerous studies have aimed to identify the risk factors associ-
ated with a worse outcome of PjP in non-HIV patients and have reported no conclusive results
[15–17]. Limited data have been published on the correlation among Pj genotypes and clinical
outcomes, and the different genotyping systems do not always allow the results obtained by
the different studies to be compared [18–20].
The aim of this study was to retrospectively evaluate the clinical and laboratory characteris-
tics related to worse outcomes in 116 PjP cases collected over a five-year period in Tor Vergata
University Hospital. In a subgroup of patients, the Pj genotypic influence on PjP prognosis
was also evaluated.
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Patients and methods
From January 2011 to January 2015, at Tor Vergata University Hospital, Rome, Italy, 507
respiratory samples were collected and evaluated for Pj presence.
One hundred thirty-six of the 507 respiratory samples, 98 (72%) bronchoalveolar lavage flu-
ids or bronchoaspirates and 38 (27.9%) sputum samples, were positive for Pj (identification of
Pj was based on IF and nested-PCR procedures, see below). A total of 130 patients tested posi-
tive, and their medical records were reviewed. One hundred sixteen of these patients received
a PjP diagnosis, and 14 were defined as colonized and were thus excluded from the study.
The patients’ demographic characteristics, including the inpatient ward, underlying medi-
cal conditions, PjP prophylaxis and treatment, radiological features, severity and outcome of
the disease, were harvested by reviewing the patients’ medical records. To collect all of the data
of the enrolled patients, a database was created ad hoc. In a subgroup of 50 patients of which a
sufficient amount of stored samples were available, data on Pj genotypes were obtained and
considered in a subsequent analysis. No significant differences in terms of sex, age, co-morbid-
ities, diseases severity, radiological findings, co-present lung infections and first-line therapy
was found between the subgroup of 50 selected subjects and the rest of population (data not
shown)
All of the patients’ personal information was treated in a confidential manner, and all clini-
cal data were collected anonymously to respect the patients’ privacy. The study was approved
by the Tor Vergata University Ethical Committee.
Definitions
PjP
PjP was defined by clinical signs of pneumonia (cough, dyspnoea and fever) and by pathologi-
cal changes of radiological examination (bilateral reticular or granular infiltrates, focal consoli-
dation, unilateral infiltrates, or nodules) associated with the simultaneous presence of Pj in
respiratory secretions.
In the respiratory secretions of 32 patients, Pj was present with other pathogens. These
cases were considered to be the result of concomitant infections, and patients received therapy
for both pathogens. These cases were defined in the text as co-present lung infections.
At admission, PjP was considered severe when the patient had a Pa02 <70 mm Hg in room
air and required supplemental oxygen, non-invasive mechanical ventilation or endotracheal
intubation.
A positive outcome of PjP was defined as clinical improvement and survival after 90 days
from the pneumonia diagnosis.
Pj colonization
Pj colonization, in contrast to Pj infection, was defined by the positive detection of Pj DNA by
PCR detection without signs or symptoms of acute pneumonia.
Typical and atypical high-resolution computed tomography (CT) PjP
radiological findings
According to previous published data [21], a fine reticular interstitial pulmonary pattern with
a prevalent perihilar distribution as well as ground glass opacities, small pneumatocoeles and/
or sub-pleural blebs were considered typical PjP radiological findings. Dense lobar consolida-
tion, nodules, miliary opacities, and pleural effusions are uncommon radiological aspects of
PjP and were thus defined as ‘atypical radiological findings’.
ID ward admission and PjP outcome
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Pj laboratory diagnosis
Pj detection and genotyping
For all samples, the detection of Pj was based on immunofluorescent procedures with mono-
clonal antibodies (MERIFLUOR1 Pneumocystis, Meridian Diagnostic, Cincinnati, OH,
USA) and nested-PCR to amplify 260 bp of the mtLSU-rRNA region as described [22]. Geno-
mic DNA was extracted from biological samples using the QIAamp DNA kit (QIAGEN, Hil-
den, Germany) according to the manufacturer’s instructions. All PCRs were carried out in
25 μL volumes containing 12.5 μL of PCR master mix 2X (Promega Italia, Milan, Italy), 5 μl
of template DNA (1 μl of the primary PCR products in the second round of PCR), and 0.6
mM of each primer, under the following conditions: 2 min at 95˚C, followed by 35 cycles of
1 min at 95˚C, 1 min at 55˚C, 1 min at 72˚C, and a final elongation of 7 min at 72˚C. In all
PCR reactions, positive and negative controls were added. Amplicons were visualized by
electrophoresis on SYBR Safe DNA-stained 1% agarose gels (Invitrogen, Life Technologies,
Monza, Italy).
A total of 50 samples (DNA and/or amplicons) still available from existing collections were
used for genotyping by sequencing. DNA was purified using the mi-PCR Purification Kit
(Metabion International AG, Planneg, Germany) and sequenced in both directions by the Bio-
Fab Research (Rome, Italy). Consensus sequences were edited using the FinchTV 1.4 software
(Geospiza, Inc, Seattle, WA, USA), queried against known Pj genotypes retrieved from Gen-
Bank and then used for identification.
Statistical analysis
A descriptive analysis of categorical variables was performed with frequency tables, while for
continuous variables, medians, ranges and standard deviations were computed. Chi squared
tests, Fischer’s tests and a log binomial regression model were adopted for both univariate and
multivariate analyses to detect the association between predictor variables and PjP severity and
outcomes. Covariates with a p-value0.05 were considered for multivariate analysis. Statisti-
cal significance was assessed for p-values0.05. Statistical analysis was performed using the
IBM SPSS software version 21, NY, U.S.A.
Results
The clinical characteristics of the 116 patients with a diagnosis of PjP are shown in Table 1.
Most (60.3%) of the patients were male, 40% of whom were over sixty. Forty percent of all PjP
cases were admitted to the Infectious Diseases Unit. Onco-haematologic diseases and HSCT
were the most common underlying diseases (37.9%), followed by HIV infection (22.4%), CLD
(16.4%), solid cancer (7.8%) and SOT (3.4%). In the group defined as ‘other clinical condi-
tions’, miscellaneous other conditions (inflammatory bowel diseases, rheumatologic diseases,
anorexia or a previous major surgery) associated with immunosuppression were recorded.
This group of patients represented 12% of the entire population.
In 32 (27.5%) patients, Pj was present in concomitance with other lung infections: in most
cases (34.4%) with pulmonary aspergillosis, in 4 cases (12.5%) with Mycobacterium tuberculo-
sis, in 2 cases with Cytomegalovirus and in the remaining 15 cases with bacterial infections,
one-third (5 patients) of which were due to Streptococcus pneumoniae. Five (15.6%) of these
patients were HIV-positive (data not shown).
Typical PjP radiological findings were present in 71.6% of the cases. Sixty-five percent of
the patient population had a severe PjP, and 26% of the study population died due to respira-
tory failure.
ID ward admission and PjP outcome
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Table 1. General characteristics of 116 patients affected by PjP, patients’ number and percentage (%).
Characteristics
N. of patients 116
Sex N. (%)
Male 70 (60.3)
Age
Mean, years, range, SD 54.4, 20–87 (16.65)
Age > 60 yrs (%) 47 (40.5)
Ward of admission N. (%)
Infectious diseases 46 (39.7)
Haematology/HSCT 36 (31.0)
Respiratory diseases 20 (17.2)
Other 14 (12.1)
Underlying diseases N. (%)
HIV 26 (22.4)
Haematological malignancy /HSCT 44 (37.9)
Solid cancer 9 (7.8)
CLD 19 (16.4)
SOT 4 (3.4)
Other clinical conditions 14 (12.1)
Co-present lung infections (tot 32) N. (%)
Aspergillosis 11 (34.4)
Pneumococcal pneumonia 5 (15.6)
Other bacterial pneumonia 10 (31.2)
CMV pneumonia 2 (6.3)
Tuberculosis 4 (12.5)
Lung TC scan findings N. (%)
Typical 83 (71.6)
Atypical 33 (28.4)
Genotype (tot 50) N. (%)
1 22 (44.0)
2 10 (20.0)
3 15 (30.0)
1/2 1 (2.0)
1/3 1 (2.0)
2/3 1 (2.0)
Previous PjP prophylaxis N (%)
Yes 28 (24.1)
No 87 (75.0)
Not known 1 (0.9)
Disease severity N (%)
Severe 75 (64.7)
Not severe 41 (35.3)
Clinical course N (%)
Recovery 86 (74.1)
Death 30 (25.9)
First line therapy N (%)
TMP/SMX 90 (77.6)
Caspofungin 10 (8.6)
(Continued )
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Only 24.1% of the studied subjects were on trimethoprim/sulfamethoxazole (TMP/SMX)
prophylaxis before the PjP occurrence, and the large majority of PjP received TMP/SMX treat-
ment. The median duration of PjP therapy was 21 days.
The genotypic analysis of Pj in the subgroup of 50 patients demonstrated that 44% of the
patients had genotype 1, 30% had genotype 3 and 10% had genotype 2. In 3 cases (6%), a
mixed genotype infection was found.
The results of a univariate analysis, which aimed to identify the variables related to PjP
severity and outcomes, are reported in Table 2.
Being older than 60 years was significantly correlated with a severe PjP (OR [95%CI] 2.52
[0.10–5.76]; p = 0.031), and a previous TMP/SMX prophylaxis and an atypical PjP radiological
finding were significantly associated with a less severe pneumonia (OR[95%CI] 0.35 [0.15–
0.84], p = 0.023, OR[95%CI] 0.32 [0.14–0.74], p = 0.009, respectively). A significant difference
in the number of patients with a severe PjP admitted in the different wards was demonstrated
(p = 0.027); in particular, a significantly higher proportion of severe PjP patients was admitted
to the Respiratory Diseases Unit (OR[95%CI] 3. 71 [1.02–13.5], p = 0.036).
The variables that were significantly associated with the worst PjP outcome and death were
being older than 60 years (OR[95%CI] 2.44 [1.05–5.70]; p = 0.036) and suffering from a CLD
(OR[95%CI] 3.26 [1.17–9.05]; p = 0.019). In contrast, admission to the Infectious Diseases
ward was a protective factor against a bad outcome and was significantly associated with fewer
deaths (OR[95%CI] 0.10 [0.03–0.36], p = 0.002).
In Table 3 the main differences between patients admitted to Infectious Diseases ward ver-
sus those admitted to the other units were reported
Of the 46 patients admitted to the Infectious Disease ward, the majority (25, 54%) were
HIV-negative; of the latter, 10 had a haematological malignancy or HSCT, 4 had solid
tumours, 2 had CLD, 2 were SOT, and 7 had one of the so-called other clinical conditions.
With respect to other wards, a significant lesser number of patients with CLD and a signifi-
cant higher number of patients with Pj genotype 3 were admitted in Infectious Diseases Unit
(OR [95%CI] 2.50 [0.49–12.7], p<0.0001; OR [95%CI] 1.36 [0.03–0.60], p<0.0001, respec-
tively). A significant lesser number of patients on TMP/SMX prophylaxis were hospitalized in
Infectious Diseases ward, nevertheless in this ward there were significantly fewer deaths (OR
[95%CI] 8.14 [2.29–28.9], p<0.0001 OR [95%CI] 0.22 [0.08–0.63], p<0.002, respectively).
Multivariate analysis (Table 4) showed that a better outcome were observed in those
patients who were admitted to the Infectious Diseases ward (OR [95%CI] 0.16 [0.05–0.55];
p = 0.004). A correlation, very close to statistical significance, with a better outcome was also
demonstrated for the previous use of TMP/SMX prophylaxis (OR[95%CI] 0.27 [0.07–1.03],
p = 0.055).
Table 1. (Continued)
Characteristics
TMP/SMX+Caspofungin 6 (5.2)
Caspofungin+Atovaquone+Primaquine+Pentamidine 2 (1.7)
Other 2 (1.7)
Not known 6 (5.2)
PjP = Pneumocystis jiroveci pneumonia; SD = standard deviation; HSCT = Haematological Stem cell
transplantation; HIV = Human Immunodeficiency Virus; CLD = Chronic Lung Diseases; SOT = Solid Organ
Transplant; CMV Cytomegalovirus; TC = computed tomography;TMP/SMX = trimethoprim/
sulfamethoxazole
https://doi.org/10.1371/journal.pone.0176881.t001
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Table 2. Univariate analysis of risk factors associate with severe pneumonia and death in 116 patients with PjP.
Risk factors associate with severe PjP Risk factors associate with death due to PjP
Severe N
(%)
Not Severe N
(%)
OR 95% CI p-value Death N
(%)
Resolution N
(%)
OR 95% CI p-value
Underlying diseases 0.071 0.017
HIV 20 (76.9) 6 (23.1) 3.33 1.12–9.88 3 (11.5) 23 (88.5) 0.59 0.14–2.44
Haematol. dis./HSCT 22 (50.0) 22 (50.0) 1.00 8 (18.2) 36 (81.8) 1.00
Solid Cancer 7 (77.8) 2 (22.2) 3.50 0.65–
18.76
4 (44.4) 5 (55.6) 3.60 0.79–
16.49
CLD 13 (68.4) 6 (31.6) 2.18 0.70–6.73 9 (47.4) 10 (52.6) 4.05 1.24–
13.21
SOT 4 (100) 0 (0) - - 0 (0) 4 (100) - -
Other 9 (64.3) 5 (35.7) 1.80 0.52–6.24 6 (42.9) 8 (57.1) 3.38 0.91–
12.45
CLD vs other 0.708 0.019
CLD 13 (68.4) 6 (31.6) 1.22 0.43–3.50 9 (47.4) 10 (52.6) 3.26 1.17–9.05
Other diseases 62 (63.9) 35 (36.1) 1.00 21 (21.6) 76 (78.4) 1.00
Age cut off 60 y 0.031 0.036
60 39 (56.5) 30 (43.5) 1.00 13 (18.8) 56 (81.2) 1.00
>60 36 (76.6) 11 (23.4) 2.52 0.10–5.75 17 (36.2) 30 (63.8) 2.44 1.05–5.70
TMP/SMX PPX 0.023 0.254
Yes 13 (46.4) 15 (53.6) 0.35 0.15–0.84 5 (17.9) 23 (82.1) 0.54 0.18–1.58
No 62 (71.3) 25 (28.7) 1.00 25 (28.7) 62 (71.3) 1.00
TC result 0.009 0.247
Typical 60 (72.3) 23 (27.7) 1.00 19 (22.9) 64 (77.1) 1.00
Atypical 15 (45.5) 18 (54.5) 0.32 0.14–0.74 11 (33.3) 22 (66.7) 1.68 0.69–4.09
First-line therapy 0.068 0.599
TMP/SMX 55 (61.1) 35 (38.9) 1.00 18 (20.0) 72 (80.0) 1.00
Caspofungine 8 (80.0) 2 (20.0) 0.55 0.51–
12.69
3 (30.0) 7 (70.0) 1.71 0.40–7.29
TMP/SMX + CAS 6 (100) 0 (0.0) - - 2 (33.3) 4 (66.7) 2.00 0.34–
11.79
CAS+PEN/PR/CLIN/ATO 2 (100) 0 (0.0) - - 1 (50.0) 1 (50.0) 4.00 0.24–67.1
Other 1 (50.0) 1 (50.0) 0.63 0.04–
10.51
1 (50.0) 1 (50.0) 4.00 0.24–67.1
Co-present lung inf. 0.893 0.731
Yes 21 (34.4) 11 (65.6) 1.06 0.45–2.49 9 (28.1) 23 (71.9) 1.17
No 54 (64.3) 30 (35.7) 1.00 21 (25.0) 63 (75.0) 1.00 0.47–2.93
Ward of admission 0.027 0.002
Infectious Dis. 32 (69.6) 14 (30.4) 1.00 5 (10.9) 41 (89.1) 0.10 0.03–0.36
Haematology/HSCT 17 (47.2) 19 (52.8) 0.39 0.16–0.97 10 (27.8) 26 (72.2) 0.32 0.10–0.99
Respiratory Dis 17 (85.0) 3 (15.0) 2.48 0.62–9.84 11 (55.0) 9 (45.0) 1.00
Other 9 (64.3) 5 (35.7) 0.79 0.22–2.79 4 (28.6) 10 (71.4) 0.33 0.07–1.40
Respiratory Dis. vs others
Wards
0.036
Respiratory Dis 17 (85.0) 3 (15.0) 3.71 1.02–13.5
Other wards 58 (60.4) 38 (39.6) 1.00
Infectious Dis. vs others
Wards
0.002
Infectious Dis. 5 (10.9) 41 (89.1) 1.00
(Continued )
ID ward admission and PjP outcome
PLOS ONE | https://doi.org/10.1371/journal.pone.0176881 May 15, 2017 7 / 14
Being older than 60 years and having typical PjP CT findings were associated with a worse
outcome and death (OR[95%CI] 2.53 [0.94–6.82], p = 0.068 and OR[95%CI] 2.97 [0.99–8.95],
p = 0.053, respectively).
The correlations among Pj genotypes, clinical PjP characteristics and outcomes of the sub-
group of 50 patients are reported in Table 5.
No correlation was found between the 3 genotypes and any of the demographic or clinical
characteristics that were evaluated. A trend for a lesser association between genotype 2 and a
co-present infection was found. All 3 subjects with mixed Pj genotypes in respiratory secre-
tions had HIV infections and a severe PjP with a typical TC scan finding. Patients with haema-
tological illness were more frequently infected by genotypes 2 and 3, patients with CLD by
genotype 1, and HIV-positive patients by all 3 genotypes. No correlation was found between
PjP severity and genotype. Most deaths were associated with Pj genotype 1 infection, but the
datum was not significant.
Discussion
In this retrospective study conducted on a cohort of HIV-positive and HIV-negative patients
with PjP, in the univariate analysis, an age>60 years and CLD were significantly associated
with more severe outcomes and death due to respiratory failure, whereas receiving TMP/SMX
prophylaxis was associated with a reduced possibility of severe PjP. The multivariate analysis,
indicated that significantly fewer deaths due to PjP were recorded in the Infectious Diseases
ward, although more severe PjP patients were admitted to this ward.
Age is a predictor that is widely used in risk stratification rules for community-acquired
pneumonia, and older age has been associated with a worse PjP prognosis in both HIV-posi-
tive and HIV-negative subjects [23–26]. The correlation between older age and death due to
PjP was recently confirmed by Roux A. and colleagues [27] in a large prospective cohort study,
in which 544 PjP cases were collected and analysed in France. This study demonstrated an
increased risk of death due to PjP for each additional year over 50 years of age.
At univariate analysis, a higher number of deaths was reported for patients with CLD who
were admitted to the Respiratory Unit. It has been demonstrated that Pj colonization worsens
bronchoconstriction in patients with chronic obstructive pulmonary disease by stimulating
local inflammation process so damaging lung function[28]. This phenomenon could facilitate
respiratory failure of patients with CLD and in part explain the significant higher number of
deaths from PjP in this group patients. However, patients with CLD are not generally consid-
ered a high-risk category for PjP, so it is also possible that there was a delay in diagnosis in this
group of patients.
Our results showed a benefit of Pj prophylaxis on PjP severity. The effect of previous TMP/
SMX prophylaxis on the severity of PjP is controversial. Previously published articles on HIV-
Table 2. (Continued)
Risk factors associate with severe PjP Risk factors associate with death due to PjP
Severe N
(%)
Not Severe N
(%)
OR 95% CI p-value Death N
(%)
Resolution N
(%)
OR 95% CI p-value
Other wards 25 (35.7) 45 (64.3) 4.56 1.60–13.0
PjP = Pneumocystis jiroveci pneumonia; OR = odds ratio, CI = confidence interval, significance at α = 0.05;; HIV = Human Immunodeficiency Virus;
Haematol. Dis. = Haematological diseases; HSCT = Haematological Stem cell transplantation; CLD = Chronic Lung Diseases; SOT = Solid Organ
Transplant; TMP/SMX = trimethoprim/sulfamethoxazole; PPX = prophylaxis;; TC = computed tomography; CAS = caspofungin; CAS+PEN/PR/CLIN/
ATO = Caspofungin+Atovaquone/ Primaquine/Clindamicine/Atovaquone
https://doi.org/10.1371/journal.pone.0176881.t002
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Table 3. General characteristics of patients with PjP admitted to Infectious Diseases ward versus those admitted on other wards.
Infectious Diseases N (%) Other wards N(%) OR 95% CI P value
Sex, N (%) 0.102
Male 32 (45.7) 38 (54.3) 1.00 -
Female 14 (30.4) 32 (69.6) 1.93 0.88–4.22
Age 0.527
Age 60 yrs (%) 29 (42.0) 40 (58.0) 1.00 -
Age > 60 yrs (%) 17 (36.2) 30 (63.8) 0.78 0.36–1.68
Underlying diseases N (%) 0.000
HIV 21 (80.8) 5 (19.2) 0.07 0.02–0.23
Hematological malignancy /HSCT 10 (22.7) 34 (77.3) 1.00 -
Solid cancer 4 (44.4) 5 (55.6) 0.37 0.08–1.63
CLD 2 (10.5) 17 (89.5) 2.50 0.49–12.7
Solid organ transplantation 2 (50.0) 2 (50.0) 0.29 0.04–2.36
Miscellaneous 7 (50.0) 7 (50.0) 0.29 0.08–1.04
Lung TC scan findings N (%) 0.920
Typical** 36 (43.4) 47 (56.6) 1.00 -
Not typical 8 (42.1) 11 (57.9) 1.05 0.38–2.89
Type of respiratory sample N (%) 0.267
BAL/ Broncho aspirate 30 (38.5) 48 (61.5) 0.63 0.27–1.43
Sputum 16 (50.0) 16 (50.0) 1.00 -
Co-present lung infections N (%) 0.555
Yes 7 (46.7) 8 (53.3) 0.72 0.24–2.14
No 39 (38.6) 62 (61.4) 1.00 -
Genotype (tot 50) N (%) 0.000
1 6 (27.3) 16 (72.7) 1.00 -
2 9 (90.0) 1 (10.0) 0.04 0.00–0.40
3 11 (73.3) 4 (26.7) 1.36 0.03–0.60
mixed 3 (100) 0 - -
Previous PCP prophylaxis N (%) 0.000
Yes 3 (10.7) 25 (89.3) 8.14 2.29–28.9
No 43 (49.4) 44 (50.6) 1.00 -
Disease severity 0.368
Severe 32 (42.7) 43 (57.3) 1.00 -
Not severe 14 (34.1) 27 (65.9) 1.44 0.65–3.12
First line therapy 0.985
TMP/SMX 36 (40.0) 54 (60.0) 1.00 -
Caspofungin 4 (40.0) 6 (60.0) 1.00 0.26–3.80
TMP/SMX+Caspofungin 3 (50.0) 3 (50.0) 0.68 0.13–3.49
Caspofungin+Atovaquone+Primaquine+Pentamidine
1 (50.0) 1 (50.0) 0.68 0.04–11.0
Other 1 (50.0) 1 (50.0) 0.68 0.04–11.0
Clinical course 0.002
Recovery 41 (47.7) 45 (52.3) 1.00 -
Death 5 (16.7) 25 (83.3) 0.22 0.08–0.63
PjP = Pneumocystis jiroveci pneumonia; OR = odds ratio, CI = confidence interval, significance at α = 0.05;; HIV = Human Immunodeficiency Virus;
Haematol. Dis. = Haematological diseases; HSCT = Haematological Stem cell transplantation; CLD = Chronic Lung Diseases; SOT = Solid Organ
Transplant; TMP/SMX = trimethoprim/sulfamethoxazole; PPX = prophylaxis;; TC = computed tomography; BAL = bronchoalveolar lavage;
CAS = caspofungin; CAS+PEN/PR/CLIN/ATO = Caspofungin+Atovaquone/ primaquine/Clindamicine/Atovaquone
https://doi.org/10.1371/journal.pone.0176881.t003
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positive patients [29,30] have demonstrated that the prior receipt of TMP/SMX was associated
with a poor outcome from severe PjP, and this phenomenon was ascribed to possible TMP/
SMX resistance acquisition. However, a correlation between the lack of prophylaxis and a worse
PjP outcome in non-AIDS patients was recently reported in a study from France [27], and a
Cochrane analysis [31] clearly showed the efficacy of Pj prophylaxis among non-HIV immuno-
compromised patients. An appropriate use of prophylaxis does not exclude its possible failure,
even if it is possible to argue that the amount of Pj in the lungs of patients under prophylaxis is
lower, thus inducing a less severe PjP clinical picture. On the contrary, the physician’s risk per-
ception of PjP in patients who are not taking prophylaxis because they are not considered to be
at risk, may be poor, and this could delay the diagnostic process and subsequent treatment,
thereby worsening the prognosis. In our study, which included numerous categories of immune
compromised hosts, only 24% of the patients had taken TMP/SMX prophylaxis before pneumo-
nia onset. Thus, it is possible that the risk of PjP has been underestimated. In our opinion, it is
necessary to reconsider the groups of patients who are at risk for PjP and could benefit from
prophylaxis and to ensure good compliance with prophylaxis by those patients for whom the
use of TMP/SMX has been established by the currently used guidelines.
In the multivariate model, age did not show to be statistically related to the PjP severity or
death. This could be related to the sample size and to the fact that age could be influenced by
other variables, such as the underlying pathology. As for the TMP/SMX prophylaxis, results
show that there is a trend through the significance, being the p-value close to the cut off we
considered for the significance. Surprisingly, in both univariate and the multivariate analysis
of our study population, although the number of severe PjP cases was high, admission to Infec-
tious Disease ward was associated with a significantly better outcome and fewer deaths. A sig-
nificantly lower number of patients with CLD was admitted to Infectious Diseases ward and
this could justify the better PjP outcome in this unit. However, an almost double number (32
versus 17) of serious PjP were admitted to Infectious Diseases respect to Respiratory Diseases
ward, in addition, at multivariate analysis the condition of CLD did not correlate either with
the clinical severity nor with death by PjP. A comparable number of HIV-positive and HIV-
negative patients were hospitalized in the Infectious Diseases ward during the study period,
and no significant differences in the outcomes of the two groups of patients were detected.
To our knowledge, this is the first report in which the infectious disease specialist approach
was related to a better prognosis of PjP. However, other authors have suggested that the
Table 4. Multivariate analysis of predictors of PjP severity and death in 116 patients with PjP.
Multivariate analysis severity Multivariate analysis death
OR (95% CI) p-value OR (95% CI) p-value
CLD vs other pathologies 0.63 (0.18–2.20) 0.464 1.45 (0.43–4.87) 0.544
Age >60 yrs vs60 yrs 1.93 (0.79–4.72) 0.152 2.53 (0.94–6.82) 0.068
TC result
not typical vs typical
0.42 (0.17–1.03) 0.059 2.97 (0.99–8.95) 0.053
Co-present lung infections
(yes vs no)
1.07 (0.43–2.68) 0.878 1.55 (0.54–4.39) 0.413
Infectious Diseases Wards
vs Other Wards
0.91 (0.34–2.42) 0.844 0.16 (0.05–0.55) 0.004
Prophylaxis administered
(yes vs no)
0.39 (0.13–1.12) 0.079 0.27 (0.07–1.03) 0.055
OR = odds ratio, CI = confidence interval, significance at α = 0.05 PjP = Pneumocystis jiroveci pneumonia; CLD = Chronic Lung Diseases; TC = computed
tomography
https://doi.org/10.1371/journal.pone.0176881.t004
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difference between being HIV-positive and HIV-negative in PjP prognosis is secondary to a
limited physicians’ alertness for HIV-negative patients regarding PjP diagnosis with a conse-
quent delay in the beginning of an appropriate treatment [24]. The HIV-infected patients were
predominantly treated by infectious disease specialists, whereas most of the non-HIV-infected
patients were usually under the charge of medical professionals other than infectious disease
specialists. The incidence of PjP in immunocompromised patients without HIV is increasing
Table 5. Genotype characteristics of 50 patients affected by PjP.
Overall
(tot 50)
Gen 1
(tot 22)
Gen 2
(tot 10)
Gen 3
(tot 15)
Gen mixed
(tot 3)
p-value
Sex, N (%) 0.290
Male 30 (60.0) 11 (50.0) 8 (80.0) 10 (66.7) 1 (33.3)
Female 20 (40.0) 11 (50.0) 2 (20.0) 5 (33.3) 2 (66.7)
OR (95% CI) 1.00 0.25 (0.04–1.45) 0.50 (0.13–1.95) 2.00 (0.16–25.4)
Age 0.242
 60 yrs (%) 28 (56.0) 10 (45.5) 5 (50.0) 10 (66.7) 3 (100.0)
> 60 yrs (%) 22 (44.0) 12 (54.5) 5 (50.0) 5 (33.3) 0
OR (95% CI) 1.00 0.83 (0.19–3.72) 0.42 (0.11–1.63) -
Underlying diseases N (%) 0.214
HIV 16 (32.0) 6 (27.3) 3 (30.0) 4 (26.7) 3 (100.0)
Other 34 (68.0) 16 (72.7) 7 (70.0) 11 (73.3) 0
OR (95% CI) 1.00 0.87 (0.17–4.54) 1.03 (0.24–4.53) -
TC findings (tot 48) N (%) 0.434
Typical 39 (78.0) 16 (84.2) 9 (100.0) 11 (78.6) 3 (100.0)
Not typical 11 (22.0) 3 (15.8) 0 3 (21.4) 0
OR (95% CI) 1.00 - 1.45 (0.25–8.58) -
Respiratory sample N (%) 0.394
BAL/ Broncho-aspirate 34 (68.0) 17 (77.3) 7 (70.0) 9 (60.0) 1 (33.3)
Sputum 16 (32.0) 5 (22.7) 3 (30.0) 6 (40.0) 2 (66.7)
OR (95% CI) 1.00 0.69 (0.13–3.68) 0.44 (0.11–1.85) 0.15 (0.01–1.98)
Co-present infections N(%) 0.243
Yes 11 (22.0) 5 (22.7) 0 5 (33.3) 1 (33.3)
No 39 (78.0) 17 (77.3) 10 (100.0) 10 (66.7) 2 (66.7)
OR (95% CI) 1.00 - 1.70 (0.39–7.36) 1.70 (0.13–22.9)
PjP PPX N (%) 0.675
Yes 6 (12.0) 2 (9.1) 1 (10.0) 2 (13.3) 1 (33.3)
No 44 (88.0) 20 (90.9) 9 (90.0) 13 (86.7) 2 (66.7)
OR (95% CI) 1.00 1.11 (0.09–13.9) 1.54 (0.19–12.3) 5.00 (0.30–82.7)
Disease severity 0.738
Severe 39 (78.0) 17 (77.3) 7 (70.0) 12 (80.0) 3 (100.0)
Not severe 11 (22.0) 5 (22.7) 3 (30.0) 3 (20.0) 0
OR (95% CI) 1.00 0.68 (0.13–3.68) 1.18 (0.24–5.90)
Clinical course (tot 51) No (%) 0.398
Recovery 39 (78.0) 15 (68.2) 9 (90.0) 12 (80.0) 3 (100.0)
Death 11 (22.0) 7 (31.8) 1 (10.0) 3 (20.0) 0
OR (95% CI) 1.00 4.20 (0.44–39.9) 1.87 (0.40–8.80 -
PjP = Pneumocystis jiroveci pneumonia; OR = odds ratio, CI = confidence interval, significance at α = 0.05;; HIV = Human Immunodeficiency Virus;
PPX = prophylaxis;; TC = computed tomography; BAL = bronchoalveolar lavage
https://doi.org/10.1371/journal.pone.0176881.t005
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[32], and chemotherapy, HSCT and solid organ transplant, and corticosteroids or other
immune suppressive medications are all considered risk factors for PjP development. How-
ever, with the exception of HIV infection, the general perception of PjP risk in other categories
of immunosuppression is low, and a recent report from the Fifth European Conference on
Infections in Leukemia (ECIL-5) stated that patients with acute lymphoblastic leukaemia or
HSCT recipients who develop PjP usually do not receive adequate prophylaxis [33].
Previous reports showed that hospitalized patients with severe infections are significantly
less likely to die if they receive care from an infectious diseases specialist and also that the bene-
fits of infectious diseases specialist consultation are more pronounced when patients are seen
earlier [34, 35]. All of these considerations led to the conclusions that the risk of PjP can be
underestimated in immunosuppressed HIV-negative patients, usually not managed by the
infectious disease specialist, and that a reduced risk perception in the patient assessment delays
the diagnostic process. An early diagnosis is critical for optimal management and for the rapid
introduction of a proper treatment, thereby influencing the outcome [23, 26].
One of the aims of our study was to evaluate the possible correlation between Pj genotypes
and outcomes; however, the reduced number of patients who were studied limited the analysis,
which resulted in no significant results.
Before we can discuss the conclusions, some of the limitations of our study need to be dis-
cussed. The retrospective nature of the study was its major limitation. The limited number of
cases collected in the different groups of underlying diseases did not allow us to detect any
prognostic differences among the different types of immunosuppression. Moreover, we could
not evaluate the influence of different treatments, and we collected no data on the time elapsed
between admission and the initiation of treatment, which recent publications have reported as
being correlated with PjP prognoses [23]. Furthermore, all patients were from a single institu-
tion, which might reduce the generalizability of the conclusions.
In conclusion, a specialist approach and TMP/SMX prophylaxis were all variables associate
with a better PjP outcome in immunocompromised hosts in our study population. More
patients need to be studied to understand whether Pj genotype characterization could be useful
in the prognostic evaluation of patients with PjP.
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